99 related articles for article (PubMed ID: 9329548)
1. First clinical results with Enzymun-Test for free PSA.
Gilson G; Lamy S; Humbel RL
Anticancer Res; 1997; 17(4B):2861-4. PubMed ID: 9329548
[TBL] [Abstract][Full Text] [Related]
2. [The incidence of the variability of the free PSA/total PSA ratio on the early diagnosis of prostate cancer].
de La Taille A; Houlgatte A; Houdelette P; Berlizot P; Fournier R; Ricordel I
Prog Urol; 1997 Jun; 7(3):455-63. PubMed ID: 9273075
[TBL] [Abstract][Full Text] [Related]
3. The clinical value of the Enzymun-Test for total and free PSA--a multicentre evaluation.
Reiter W
Anticancer Res; 1999; 19(6C):5559-62. PubMed ID: 10697616
[TBL] [Abstract][Full Text] [Related]
4. Total and free PSA: a methodical and clinical evaluation of five assays.
Reiter W; Stieber P; Schmeller N; Nagel D; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1997; 17(6D):4759-65. PubMed ID: 9494603
[TBL] [Abstract][Full Text] [Related]
5. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
6. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
7. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
Stephan C; Lein M; Jung K; Schnorr D; Loening SA
Cancer; 1997 Jan; 79(1):104-9. PubMed ID: 8988733
[TBL] [Abstract][Full Text] [Related]
8. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
[TBL] [Abstract][Full Text] [Related]
9. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
[TBL] [Abstract][Full Text] [Related]
10. Increased discrimination between benign prostatic hyperplasia and prostate cancer through measurement of percentage free PSA.
Wolff JM; Boeckmann W; Effert PJ; Habib FK; Jakse G
Anticancer Res; 1997; 17(4B):2993-4. PubMed ID: 9329583
[TBL] [Abstract][Full Text] [Related]
11. Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate.
Jung K; Meyer A; Lein M; Rudolph B; Schnorr D; Loening SA
J Urol; 1998 May; 159(5):1595-8. PubMed ID: 9554361
[TBL] [Abstract][Full Text] [Related]
12. The ratio of free to total prostate specific antigen: an advantageous addition in the differential diagnosis of benign hyperplasia and cancer of the prostate?
Reiter W; Stieber P; Schmeller N; Nagel D; Jansen HM; Schambeck C; Fabricius PG; Pahl H; Mattes M; Constabel H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2987-91. PubMed ID: 9329582
[TBL] [Abstract][Full Text] [Related]
13. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
[TBL] [Abstract][Full Text] [Related]
14. Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer.
Filella X; Alcover J; Corral JM; Molina R; Beardo P; Ballesta AM
Anticancer Res; 2001; 21(5):3717-20. PubMed ID: 11848550
[TBL] [Abstract][Full Text] [Related]
15. Effect of NIH-IV prostatitis on free and free-to-total PSA.
Stancik I; Lüftenegger W; Klimpfinger M; Müller MM; Hoeltl W
Eur Urol; 2004 Dec; 46(6):760-4. PubMed ID: 15548444
[TBL] [Abstract][Full Text] [Related]
16. Free-to-total prostate specific antigen ratio in clinical staging of prostate cancer.
Maeda H; Arai Y; Ishitoya S; Okubo K; Aoki Y; Okada T; Maekawa S
Hinyokika Kiyo; 1998 May; 44(5):307-11. PubMed ID: 9656100
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer detection by prostate-specific antigen-related parameters.
Segawa N; Gohji K; Iwamoto Y; Ueda H; Katsuoka Y
Hinyokika Kiyo; 2003 Jul; 49(7):405-10. PubMed ID: 12968483
[TBL] [Abstract][Full Text] [Related]
18. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
19. [Changes in the levels of prostate-specific antigen and its molecular forms with alpha 1-antichymotrypsin in patients with benign prostatic hyperplasia].
Grigor'ev ME; Mazo EB; Chekhonin VP
Urol Nefrol (Mosk); 1998; (4):33-7. PubMed ID: 9727319
[TBL] [Abstract][Full Text] [Related]
20. [Free/total ratio of prostate-specific antigen (PSA) for prostate cancer detection in patients with gray zone PSA level].
Tanaka M; Murakami S; Igarashi T; Abe T; Suzuki K; Sekita N; Shimazaki J
Hinyokika Kiyo; 1997 Dec; 43(12):855-60. PubMed ID: 9488932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
